CHIRON CORP
10-C, 1996-01-29
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: ARCH FUND INC, 24F-2NT, 1996-01-29
Next: FIDELITY MT VERNON STREET TRUST, NSAR-B, 1996-01-29



<PAGE>
                               UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                           Washington, D.C.  20549

                                 FORM 10-C

              REPORT BY ISSUER OF SECURITIES QUOTED ON NASDAQ
                       INTERDEALER QUOTATION SYSTEM

   FILED PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
                   AND RULE 13a-17 OR 15d-17 THEREUNDER

                            Chiron Corporation
- -------------------------------------------------------------------------------
               (Exact name of issuer as specified in charter)

          4560 Horton Street, Emeryville, California  94608-2916
- -------------------------------------------------------------------------------

                 (Address of principal executive offices)

Issuer's telephone number, including area code  (510) 655-8730
                                               --------------------------------
                 I. CHANGE IN NUMBER OF SHARES OUTSTANDING

Indicate  any  change (increase or decrease) of 5% or  more  in  the
number of shares outstanding:

1.     Title of security  Common Stock, $0.01 par value
                         ------------------------------------------------------
2.     Number of shares outstanding before the change   39,950,993
                                                     --------------------------
3.     Number of shares outstanding after the change    41,952,078
                                                     --------------------------
4.     Effective date of change   January 22, 1996
                                -----------------------------------------------

5.     Method of change:
       Specify   method   (such   as   merger, acquisition, exchange,
       distribution, stock split, reverse split, acquisition of stock for
       treasury,  etc.)  Warrant  and  stock  option  exercises, issuances
                         ------------------------------------------------------
       under Employee Stock Purchase Plan, acquisition.
       ------------------------------------------------------------------------
       Give  brief description of transaction   Issuance of stock  as  a  result
                                                --------------------------------
       of (1) exercises of stock options under stock option  plan,
       -------------------------------------------------------------------------
       (2)  quarterly stock purchases under Employee Stock Purchase  Plan
       -------------------------------------------------------------------------
       (3)  acquisition of Viagene, Inc. in September 1995  and  (4)  exercise
       -------------------------------------------------------------------------
       of warrants
       -------------------------------------------------------------------------

                       II. CHANGE IN NAME OF ISSUER

1.     Name prior to change    N/A
                             --------------------------------------------------

2.     Name after change
                           ----------------------------------------------------

3.     Effective date of charter amendment changing name
                                                          ---------------------

4.     Date of shareholder approval of change, if required
                                                            -------------------

Date January 26, 1996

                  /s/ William G. Green, Senior Vice President & General Counsel
                  -------------------------------------------------------------
                                     (Officer's  signature & title)


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission